-
Co-Assembled Nanoparticles Comprising Sorafenib and Hederagenin Derivative for Enhanced Anti-Hepatic Fibrosis Activity
17 Jul 2025 18:58 GMT
… without any further purification. Sorafenib (Ark Pharma Scientific, … -mediated ASGPR targeting. Sorafenib, released from hepatocytes, … Phosphate buffer solution; Sor, Sorafenib; STING, Stimulator of … gefitinib resistance in lung cancer by activating ERBB3 …
-
Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with PD-L1 Expression ≥1%
16 May 2025 11:14 GMT
… pCR and MPR.
About Lung Cancer
Lung cancer is the leading cause … been previously treated with sorafenib.
OPDIVO® (nivolumab) … metastatic non-small cell lung cancer, in combination with … cell lung cancer; Checkmate 816–neoadjuvant non-small cell lung cancer, …
-
Camrelizumab Combo Doubles 5-Year Survival in Phase 3 Lung Cancer Trial
02 Apr 2025 23:47 GMT
… patients with advanced squamous lung cancer, according to a press … at the 2025 European Lung Cancer Congress (ELCC). The trial … Center consistently shows that lung cancer has the highest incidence … 15.2 months with sorafenib. Median progression-free survival …
-
Bristol Myers Squibb Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo for Resectable Non-Small Cell Lung Cancer in Patients with Tumor Cell PD-L1...
28 Mar 2025 13:11 GMT
… of four tumor types: lung cancer, bladder cancer, esophageal … pathologic response.
About Lung Cancer
Lung cancer is the leading cause … been previously treated with sorafenib. This indication is … lung cancer; Checkmate 816–neoadjuvant non-small cell lung cancer, …
-
Bristol Myers Squibb Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer
19 Feb 2025 12:09 GMT
… positive) non-small cell lung cancer (NSCLC).
OPDIVO® (nivolumab … been previously treated with sorafenib. This indication is … metastatic non-small cell lung cancer, in combination with … cell lung cancer; Checkmate 816–neoadjuvant non-small cell lung cancer, …
-
A Comprehensive Review of Advances in Molecular Mechanisms and Targeted Therapies for the Specific Type of Cystic Lung Cancer
11 Feb 2025 15:06 GMT
… is the most neuroendocrine lung tumor, and it also … Lung cancers associated with cystic airspaces: CT features and pathologic correlation. Lung Cancer … Raez LE. Efficacy of sorafenib, a multi-tyrosine kinase … -L1 expression in rare lung tumors. Pathol Oncol Res. …
-
Radiation-Induced Liver Injury: An Overview
10 Sep 2025 15:21 GMT
… addition to the most common lung cancer and female breast cancer, colorectal … . Combination intensity-modulated radiotherapy and sorafenib improves outcomes in hepatocellular carcinoma …
-
The Radiosensitizing Effect of Tumor-Derived Microparticles Co-Loaded with Sorafenib and Gold Nanoparticles on Hepatocellular Carcinoma
28 Apr 2025 08:51 GMT
… therapy drugs such as sorafenib, lenvatinib and donafenib … cell-derived microparticles, final sorafenib concentration 16 μM), RT … (MPSF@AuNP) encapsulating sorafenib with gold nanoparticles to … based targeted chemotherapy in lung cancer patients with malignant …
-
Folic Acid-Targeted Liposome-Based Nanoparticle Loaded with Sorafenib for Liver Cancer Therapy
29 Mar 2025 11:12 GMT
… through FC targets. Sorafenib-equipped liposomes exhibit … dialyzing to remove free sorafenib, filtration, and lyophilization, … non-small cell lung cancer phase III clinical trials … metabolic aspects of sorafenib resistance in hepatocellular carcinoma …
-
Clinical Significance and Molecular Annotation for PD-L1 Negative Advanced Non-Small Cell Lung Cancer with Sensitivity to Responsive to Dual PD-1/CTLA-4 Blockade
06 Sep 2024 05:53 GMT
… and mortality rates of lung cancer have been steadily increasing … with various malignancies, including lung cancer.35 Finally, we combined … carcinoma previously treated with sorafenib: the checkmate 040 … with non-small-cell lung cancer (CheckMate 9LA): an …
About
© 1995-2025